The U.S. Food and Drug Administration raised concerns about the effectiveness of Capricor Therapeutics' experimental stem cell treatment for Duchenne muscular dystrophy ahead of a scheduled advisory panel meeting. According to internal documents obtained by STAT, the FDA concluded that the drug, called deramiocel, failed to meet the goals of its Phase 3 clinical trial, contradicting the company's earlier assertion that it achieved both primary and secondary endpoints in a large, randomized study conducted last year. This revelation comes amid growing scrutiny over the reliability of clinical data submitted by pharmaceutical firms seeking regulatory approval for treatments targeting rare diseases. In December 2025, Capricor announced that deramiocel demonstrated statistically significant improvements in preserving upper arm strength and delaying the onset of heart failure among teenage boys and young men with Duchenne muscular dystrophy, a condition that typically leads to death by early adulthood due to cardiac complications. These results were considered groundbreaking because they addressed a critical unmet need in a patient population with limited therapeutic options. However, the FDA's recent assessment challenges these findings, suggesting that the trial's design and subsequent statistical analyses may have compromised the validity of the outcomes. The FDA's concerns center around modifications Capricor made to the trial's statistical analysis plan, which the agency argues weakened the overall robustness of the data. These changes, according to the documents, introduced uncertainties into what initially appeared to be promising results. The advisory panel, set to convene later this month, will evaluate the FDA's findings alongside Capricor's response before rendering a recommendation on whether the drug should proceed toward potential approval. The panel's decision could significantly influence future research directions in treating Duchenne muscular dystrophy, particularly regarding the role of stem cell therapies. Capricor's initial announcement in December generated considerable optimism within the medical community, as Duchenne muscular dystrophy has long been resistant to conventional treatments. The disease affects approximately 1 in 5,000 male children and is characterized by progressive muscle degeneration leading to loss of mobility and eventual respiratory or cardiac failure. The prospect of a treatment that could delay heart failure and maintain functional independence represented a major breakthrough. However, the FDA's current stance suggests that the evidence supporting these claims requires further validation. The FDA's evaluation of deramiocel follows a broader trend of increased regulatory rigor in reviewing clinical trials for rare diseases. In recent years, agencies worldwide have become more cautious about approving drugs based on preliminary or potentially flawed data, especially when the conditions being treated carry high mortality rates. This approach aims to ensure that approved therapies genuinely offer meaningful benefits to patients rather than relying on statistical anomalies or methodological flaws in trial design. Capricor faces mounting pressure to address the FDA's concerns, as the outcome of the advisory panel meeting will determine whether the company can move forward with its application for approval. If the panel concludes that the data are insufficient, Capricor may need to conduct additional studies or refine its analytical methods before resubmitting its request. Such delays could prolong the wait for families affected by Duchenne muscular dystrophy, many of whom have exhausted existing treatment options and are desperate for alternatives. The company has yet to formally respond to the FDA's latest findings, though it is expected to present its case during the upcoming hearing.
3 reports
STAT NewsIndependentCenterFactual 90Objective 954 days agoThe Food and Drug Administration (FDA) raised concerns about the efficacy of Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy, stating that the drug did not meet the objectives of a Phase 3 trial. This contradicts Capricor's previous claims from December 2025, which asserted that the treatment, called deramiocel, achieved both primary and secondary endpoints in a large, randomized study. The trial focused on teenagers and young men who have lost the ability to walk, a group with limited treatment options. Capricor argued that the drug preserved upper-arm function and potentially prevented heart failure, which is common in Duchenne patients. The FDA's findings suggest a discrepancy between the company's assertions and the agency's evaluation of the trial results.
Bias read (Center): The article presents information about a regulatory review of a pharmaceutical product without overtly endorsing or criticizing either the FDA or Capricor Therapeutics. While the subject involves a significant health issue and potential regulatory action, the framing remains neutral, focusing on the
Why factuality (90): This article presents the FDA's position regarding the Capricor drug's Phase 3 trial results accurately, matching the cross-source consensus. It provides specific details about the trial and the company's previous claims, without embellishment or contradiction.
Why objectivity (95): The article maintains a neutral tone, presenting facts without emotional language or editorializing. It clearly states the FDA's stance and the company's prior claims without taking sides.
STAT NewsIndependentCenterFactual 80Objective 85yesterday STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and moreThe article discusses two main topics. First, a U.S. Food and Drug Administration (FDA) advisory panel rejected a Duchenne muscular dystrophy treatment developed by Capricor Therapeutics, citing concerns over the reliability of the drug's effectiveness data. The panel voted 9 to 3 against approval, criticizing the company for altering the study's statistical analysis plan, which undermined the data's robustness. Second, the Federal Trade Commission (FTC) filed a lawsuit against Hims & Hers, alleging deceptive practices related to consumer health data handling and subscription billing. The FTC claims the company misleads users about data sharing, fails to clarify subscription terms, and does not allow patients to review or consent to treatments before being billed.
Bias read (Center): The article presents both stories in a balanced manner without overtly favoring either side. It reports on regulatory decisions and legal actions without taking a clear ideological stance. The framing remains neutral, focusing on factual developments rather than advocating for any particular policy.
Why factuality (80): The article confirms the FDA advisory panel's rejection of the drug's effectiveness data, consistent with the cross-source consensus. It also references the FTC lawsuit against Hims & Hers, which is reported accurately. Some subjective descriptions of the Pharmalot campus add flavor but don't detrac
Why objectivity (85): While the article uses some playful language ('English breakfast,' 'long, luxurious naps'), these are part of the publication's style and do not indicate bias. The reporting on the FDA and FTC actions remains objective.
STAT NewsIndependentCenterFactual 75Objective 803 days ago STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and moreThe article discusses two main topics. First, the U.S. Food and Drug Administration (FDA) stated that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy failed to meet the objectives of a Phase 3 trial, contradicting the company's previous claims. The FDA's findings were based on newly released documents ahead of a hearing where advisory panel members will evaluate the drug. Second, the article reports that global funding for HIV prevention dropped significantly in 2025, with government contributions declining by over $1.5 billion to $7.3 billion—a 18% decrease marking the lowest level in nearly two decades. This decline threatens to reverse progress against the HIV epidemic, particularly in sub-Saharan Africa where prevention programs rely heavily on donor support. While the U.S. remains the largest contributor to government donor funding, it has been criticized for recent funding cuts.
Bias read (Center): The article presents information from multiple perspectives without overt ideological slant. It reports on FDA regulatory decisions and international health funding trends, which are politically sensitive but presented factually. The tone remains neutral, focusing on data and expert assessments, and
Why factuality (75): The article reports that the FDA contradicts Capricor's claims about the Phase 3 trial results, aligning with the cross-source consensus. It mentions the decline in HIV funding, which is corroborated by the UNAIDS report referenced in the text. However, the article includes some subjective language
Why objectivity (80): The tone remains professional and informative, though there are some whimsical phrases like 'witch’s brew' and 'smashing day.' These are stylistic choices rather than overt bias, so the overall objectivity score remains high.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
United States
